Tucson pharmaceutical company sells exclusive option for cancer drug in deal worth up to $190 million

Sucampo unveiled Monday its agreement with Tucson, Arizona-based Cancer Prevention Pharmaceuticals Inc. for the option to acquire an exclusive license to commercialize for a drug candidate in Phase III clinical trials. The therapy is aimed at treating a genetic condition called Familial Adenomatous Polyposis, or FAP, which can develop into colon cancer if it’s left untreated.

Click here for full article